Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note published on Saturday morning. The firm issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

Shares of NASDAQ BCLI opened at $0.86 on Friday. Brainstorm Cell Therapeutics has a 1 year low of $0.72 and a 1 year high of $10.05. The stock has a market capitalization of $5.61 million, a P/E ratio of -0.18 and a beta of 0.60. The company’s 50-day moving average is $1.38 and its 200 day moving average is $1.70.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.